Supplementary Figure 7: YAP1 inhibition sensitizes tumors to RAF-MEK inhibition in vivo.
From: The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
(a) Average tumor volume of xenografts generated from A2058 cells infected with either scrambled control shRNA or YAP1 shRNA (n = 10/group, +s.e.m.). (b) Waterfall plot indicating fold change in tumor volume upon vemurafenib or trametinib treatment of A2058 xenografts infected with either scrambled control shRNA or YAP1 shRNA (n = 8–12/group, ±s.e.m.). (c) Immunoblot analysis for each indicated protein in lysates from representative A2058 xenograft tumors. d, Average tumor volume of xenografts generated from HT29 cells infected with either scrambled control shRNA or YAP1 shRNA (n = 10/group, +s.e.m.). (e) Waterfall plot indicating fold change in tumor volume upon vemurafenib or trametinib treatment of HT29 xenograft model infected with either scrambled control shRNA or YAP1 shRNA (n = 8–12/group, ±s.e.m.). (f) Immunoblot analysis for each indicated protein in lysates from representative HT29 xenograft tumors. (g) Waterfall plot indicating fold change in tumor volume upon trametinib treatment of MOR/CPR xenograft model infected with either scrambled control shRNA or YAP1 shRNA (n = 8–12/group, ±s.e.m.). (h) Immunoblot analysis for each indicated protein in lysates from representative MOR/CPR xenograft tumors.
